Imaging Genetics of Laryngeal Dystonia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorKristina Simonyan

About this trial

The contribution of genetic risk factors to the development of focal dystonias is evident. However, understanding of how variations in the causative gene expression lead to variations in brain abnormalities in different phenotypes of dystonia (e.g., familial, sporadic) remains limited. The research program of the investigators is set to determine the relationship between brain changes and genetic risk factors in laryngeal dystonia (or spasmodic dysphonia). The researchers use a novel approach of combined imaging genetics, next-generation DNA sequencing, and clinical-behavioral testing. The use of a cross-disciplinary approach as a tool for the discovery of the mediating neural mechanisms that bridge the gap from DNA sequence to the pathophysiology of dystonia holds a promise for the understanding of the mechanistic aspects of brain function affected by risk gene variants, which can be used reliably for the discovery of associated genes and neural integrity markers for this disorder. The expected outcome of this study may lead to better clinical management of this disorder, including its improved detection, accurate diagnosis, and assessment of the risk of developing dystonia in family members.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Males and females of diverse racial and ethnic background, with age across the lifespan;

Laryngeal Dystonia patients

phenotype: adductor or abductor

genotype: familial or sporadic

Disqualifiers

Subjects who are incapable of giving informed consent.

Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding.

Subjects with past or present medical history of (a) major neurological problems, such as stroke, movement disorders (other than LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder; (c) laryn¬geal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.

Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles.

Trial population

laryngeal dystonia unaffected relatives of laryngeal dystonia patients voice tremor muscle tension dysphonia

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • MRI

    Other intervention

    Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

  • Blood draw

    Procedure/Surgery

    Blood samples will be collected, the DNA will be extracted and banked for genetic studies.

Treatment groups

410 Participants
are divided into 4 treatment groups
Group A: Laryngeal Dystonia2 interventions
Group B: Unaffected relatives of laryngeal dystonia patients2 interventions
Group C: Voice tremor2 interventions
Group D: Muscle tension dysphonia2 interventions

Trial outcomes

Primary outcomes

1

Brain changes in laryngeal dystonia

Identify imaging biomarker of laryngeal dystonia

Time frame
5 years

Secondary outcomes

1

Genes responsible for laryngeal dystonia

Identify genetic mutations responsible for laryngeal dystonia

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kristina Simonyan

Lead sponsor

Massachusetts Eye and Ear Infirmary

Sponsor institution

National Institute on Deafness and Other Communication Disorders (NIDCD)

Collaborator